Exosomes as Critical Agents of Cardiac Regeneration Triggered by Cell Therapy  by Ibrahim, Ahmed Gamal-Eldin et al.
Stem Cell Reports
ArticleExosomes as Critical Agents of Cardiac Regeneration Triggered by Cell
Therapy
Ahmed Gamal-Eldin Ibrahim,1 Ke Cheng,1 and Eduardo Marba´n1,*
1Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
*Correspondence: eduardo.marban@cshs.org
http://dx.doi.org/10.1016/j.stemcr.2014.04.006
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYThe CADUCEUS trial of cardiosphere-derived cells (CDCs) has shown that it may be possible to regenerate injured heart muscle previ-
ously thought to be permanently scarred. Themechanisms of benefit are known to be indirect, but themediators have yet to be identified.
Here we pinpoint exosomes secreted by human CDCs as critical agents of regeneration and cardioprotection. CDC exosomes inhibit
apoptosis and promote proliferation of cardiomyocytes, while enhancing angiogenesis. Injection of exosomes into injuredmouse hearts
recapitulates the regenerative and functional effects produced by CDC transplantation, whereas inhibition of exosome production by
CDCs blocks those benefits. CDC exosomes contain a distinctive complement of microRNAs, with particular enrichment of miR-
146a. Selective administration of amiR-146amimic reproduces some (but not all) of the benefits of CDC exosomes. The findings identify
exosomes as key mediators of CDC-induced regeneration, while highlighting the potential utility of exosomes as cell-free therapeutic
candidates.INTRODUCTION
Cardiosphere-derived cells (CDCs) stimulate regenera-
tion, angiogenesis, and functional improvement in the
infarcted myocardium (Kreke et al., 2012; Smith et al.,
2007) by indirect mechanisms; most of the newly
regenerated myocardium and vasculature are of endoge-
nous origin (Chimenti et al., 2010), and the beneficial
effects of CDCs persist long after the injected cells
have been cleared (Malliaras et al., 2012). CDCs are
rich biological factories that secrete many growth factors
and cytokines (Stastna et al., 2010), but a possible role
for exosomes has yet to be considered. Exosomes are
lipid bilayer nanovesicles secreted by a variety of cells
when multivesicular endosomes fuse with the plasma
membrane (Denzer et al., 2000). Although first described
decades ago (Pan and Johnstone, 1983; Pan et al., 1985),
exosomes have attracted new interest sparked by the
recognition that they play important roles in para-
crine and autocrine signaling (Johnstone, 2005). Exo-
somes transfer proteins and RNA (Lugini et al., 2012),
notably microRNAs (miRNAs) (Zhu and Fan, 2011),
from cell to cell, rationalizing potential applications in
clinical therapeutics (Arslan et al., 2013; Hergenreider
et al., 2012; O’Loughlin et al., 2012). Here, we test the
concept that CDC-secreted exosomes (CDC exosomes
for short), and specifically the miRNAs transferred
by these exosomes, mediate the protective effects
of human CDCs in a murine model of myocardial
infarction (MI).606 Stem Cell Reports j Vol. 2 j 606–619 j May 6, 2014 j ª2014 The AuthorsRESULTS
CDC Exosomes Enhance Angiogenesis and Promote
Cardiomyocyte Survival and Proliferation
Exosomes were isolated from serum-free media condi-
tioned over 15 days by cultured human CDCs (or normal
human dermal fibroblasts [NHDFs] as a therapeutically
inert control) (Smith et al., 2007) (Figure S1 available on-
line). By the end of the conditioning period, most of the
CDCs remained alive despite the absence of regular media
changes (Figures S1B and S1C). Purified exosome pellets
were enriched in RNA (Figure 1A). We confirmed that
the RNA resides within exosomes by exposing the pellet
to RNase A in the presence of 5% triton (Figure 1B), with
proteinase K added to dissociate protein complexes that
may shield RNA (Arroyo et al., 2011). Mass spectrometry
confirmed the presence of conserved exosomal biogenesis
proteins (Figure 1C) including CD63, which we used (by
prior convention; e.g., Singh et al., 2012b) to quantify exo-
some yield (Figure 1D). Transmission electron microscopy
revealed most exosomes to be 30–90 nm in diameter,
although smaller and larger particles were also present
(Figures 1E and 1F), consistent with reports of exosomes
derived from vascular cells (Hergenreider et al., 2012;
Sahoo et al., 2011).
In vitro assays revealed major effects of CDC exo-
somes on angiogenesis, cardiomyocyte proliferation, and
apoptosis. CDC exosomes, but not NHDF exosomes, pro-
moted tube formation in human umbilical cord endothe-
lial cells, indicative of enhanced angiogenesis (Figure 1G).
Figure 1. Characterization of CDC Exosomes
(A) RNA content measured in exosome pellets derived from CDCs and NHDFs compared to conditioned media from both samples.
(B) Exosomal RNA is protected from RNase degradation by the lipid bilayer membrane of exosomes. Exosome pellets were treated with
RNase A in the presence or absence of triton to assess protection from RNase-mediated degradation. All samples were treated with
proteinase K to dissociate complexes which might otherwise shield RNA (n = 4 technical replicates).
(C) CDC and NHDF exosomes express ubiquitous exosome markers as revealed by mass spectrometry.
(D) Exosome quantification from CDC- and NHDF-conditioned media based on expression of the conserved CD63 marker (n = 3 technical
repeats).
(E) Exosomes isolated from CDCs visualized by transmission electron microscopy. Three populations (by size) are illustrated.
(F) Size distribution of exosomes derived from CDCs, measured from transmission electron microscopic images; n = 100 exosomes counted.
CDC exosomes enhance angiogenesis and promote neonatal rat cardiomyocyte (NRCM) survival and proliferation in vitro.
(G) CDC exosomes stimulate angiogenesis compared to NHDF exosomes in a HUVEC angiogenesis assay. Quantification of angiogenesis
assay by HUVEC tube length (vascular cell basal medium, VCGM as a negative control and vascular cell growth medium, VCGM, as a positive
control). n = 3 technical replicates per group.
(legend continued on next page)
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atedmore than those exposed to NHDF exosomes ormedia
only, as evidenced by higher proportions of Ki67-positive
nuclei (Figure 1H). In addition, CDC-exosome-treated
cardiomyocytes exhibited fewer terminal deoxynucleoti-
dyltransferase nick end labeling (TUNEL)-positive nuclei
(Figure 1I). Thus, CDC exosomes stimulate angiogenesis,
promote cardiomyocyte proliferation, and decrease pro-
grammed cell death. These effects reproduce those of the
parent CDCs (Kreke et al., 2012).
CDC Exosomes Improve Cardiac Function, Impart
Structural Benefits, and Increase Viable Mass after MI
CDCs stimulate functional improvement and regeneration
in the infarcted myocardium in both animals and humans
(Kreke et al., 2012). To assess therapeutic efficacy in an
established preclinical model, we induced acute MI in
immunodeficient mice then injected CDC exosomes,
NHDF exosomes, or serum-free media into the MI border
zone (Cheng et al., 2014; Li et al., 2010; Smith et al.,
2007). At 15 and 30 days after injection, global heart
function was greater in animals injected with CDC exo-
somes compared with NHDF exosomes or media controls
(Figure 2A). At the histological level, CDC-exosome-treated
hearts exhibited decreased scarmass, increased viablemass,
and increased infarcted wall thickness compared to NHDF
exosome and media controls (Figures 2B–2E). Proinflam-
matory cytokine levels were also lower in CDC-exo-
some-treated hearts (Figure S2). In all these respects, CDC
exosomes mimic the known benefits of CDCs themselves
(Kreke et al., 2012).
The acute MI model, while used extensively to assess
bioactivity, cannot distinguish cardioprotective effects
from genuine regeneration (Malliaras et al., 2013). To
make this distinction, we performed another set of experi-
ments in which we injected exosomes 21 days after MI,
when myocardial scar is well established (Virag and Murry,
2003). Three weeks later, hearts injected with CDC exo-
somes showed multiple structural and functional benefits:
improved ejection fraction (Figure 2F; also improved frac-
tional area change, Figure S3A), lower scar mass (represen-
tative images in Figure 2G and pooled data in Figure 2H),
higher viable mass (Figure 2I), and thicker infarcted walls
(Figure 2J). Moreover, hearts treated with CDC exosomes
exhibited less chamber dilation (Figures S3B and S3C),
smaller infarct circumference (Figure S3D), and diminished
compensatory myocyte hypertrophy (Figures S3E and S3F)
relative to the grossly distorted control hearts. The density(H and I) CDC exosomes promote proliferation (Ki67-positive nuclei;
neonatal cardiomyocytes; n = 4 technical replicates per group.
*p < 0.05, **p < 0.01, and ***p < 0.001 using one-way ANOVA (Tuke
Figure S1.
608 Stem Cell Reports j Vol. 2 j 606–619 j May 6, 2014 j ª2014 The Authorsof microvessels was increased (Figures 2K and S3G) and
apoptotic cardiomyocyte nuclei were less frequent (Figures
S3H and S3I) in CDC-exosome-treated hearts. The net
growth of new myocardium in the setting of established
scar fulfills the central criterion for therapeutic regenera-
tion (Makkar et al., 2012); the improvement in function
and the attenuation of adverse remodeling attest to
the physiological significance of the tissue changes. We
conclude that CDC exosomes indeed mediate genuine car-
diac regeneration, while favoring angiogenesis and tissue
preservation.
Inhibition of Exosome Secretion Attenuates CDC
Benefit
If exosomes mediate the therapeutic effects of CDC trans-
plantation, then inhibition of exosome secretion would
logically be expected to block the benefits. To test this
concept, we treated CDCs with GW4869, a reversible
inhibitor of neutral sphingomyelinase that prevents exo-
some release (Kosaka et al., 2010; Trajkovic et al., 2008).
Exposure to GW4869 blocked exosome production in
a dose-dependent manner (Figure 3A), with complete sup-
pression at 20 mM (a dose without apparent short-term
cytotoxicity; e.g., no impairment of proliferation; Fig-
ure 3B). Suppression of exosome release abrogated the indi-
rect benefits of CDCs in vitro because media conditioned
by GW4869-treated CDCs did not enhance cardiomyocyte
proliferation or attenuate apoptosis (Figures 3C and 3D).
Spiroepoxide, a specific irreversible inhibitor of neutral
sphingomyelinase (Trajkovic et al., 2008), mimicked the
antiapoptotic effects of GW4869 on stressed cardiomyo-
cytes (Figures S4A and S4B). In vivo, CDCs pretreated
with GW4869 exerted no functional (Figure 3E) or struc-
tural (Figures 3F–3I) benefits in acute MI, in contrast to
vehicle-only (DMSO) controls that conferred all the ex-
pected therapeutic effects of CDCs (Kreke et al., 2012).
Thus, exosome secretion by CDCs is required for CDC-
mediated benefits in vitro and in vivo.
CDCExosomes Are Enriched inmiR-146a, which Plays
an Important Role in MI Pathology
To investigate the basis of the therapeutic benefit of CDC
exosomes, we compared their miRNA repertoire to that
of NHDF exosomes using a PCR microarray of the 88
best-defined miRNAs. The miRNA content of the two cell
types differed dramatically. Forty-three miRNAs were
differentially present in the two groups; among these,
miR-146a was the most highly enriched in CDC exosomesH) and survival (inhibition of TUNEL-positive nuclei; I) in cultured
y’s post hoc test). Data are represented as mean and SEM. See also
Figure 2. CDC Exosomes Produce Structural and Functional Benefits in Mouse Hearts after MI
(A) In the acute model, SCID Beige mice underwent MI and hearts were injected with CDC exosomes, NHDF exosomes, or vehicle (control).
Animals (n = 8 animals per group) were echoed at days 1, 15, and 30 and were then sacrificed for histological analysis. CDC exosomes
increase left ventricular ejection fraction (LVEF).
(legend continued on next page)
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4B, and S5). Furthermore, miR-146a tissue levels were
increased in post-MI hearts from animals injected with
CDC exosomes relative to those injected with NHDF exo-
somes (Figure 4C), rendering plausible the idea that CDC
exosomes might act via miR-146a transfer. Exposure
of neonatal rat cardiomyocytes to a miR-146a mimic
increased cardiomyocyte viability and protected against
oxidant stress (Figures 4D and S6A). Whole-transcriptome
microarrays revealed downregulation of Irak1 and Traf6,
two signaling mediators of the TLR-NFkB axis that are
known targets of miR-146a (Huang et al., 2012; Wang
et al., 2013) (Figure 4E). Ingenuity pathway analysis
(Thomas and Bonchev, 2010) pointed to changes in
pathways involved in cell survival, cell cycling, cellular
organization, and morphology, all of which are relevant
to ischemic injury (Figure S5D) and share links to the basal
transcription factor Myc (Figure S5E).
To probe the biological role of miR-146a in myocardial
injury, we induced acute MI in miR-146a knockout (146a
KO) mice and compared them with wild-type mice of the
same strain (WT), as well as 146a KO mice ‘‘rescued’’ by in-
jection of a miR-146a mimic at the time of MI (146a KO-R).
After MI, the 146a KO mice showed deeply impaired heart
function and adverse remodeling compared to WTor 146a
KO-R (Figures 4F and 4G). Histological analysis revealed
significant increases in scar mass (Figure 4H) and decreases
in infarct wall thickness in the 146a KO, but not in WT
or 146a KO-R (Figure 4J). Viable mass was greatest in the
146a KO-R group (Figure 4I), perhaps indicating a supra-
physiological effect of the injected miR-146a mimic. These
findings point to a critical role of miR-146a in MI and give
reason to suspect that miR-146a may mediate some of the
therapeutic benefits of CDC exosomes.
miR-146a Leads to Thicker Infarct Wall Thickness and
Increased Viable Tissue in a Mouse Model of MI
To investigate the contribution of miR-146a to the greater
exosome effect, we developed miR-146a-deficient exo-
somes by transfecting CDCs with a miR-146a hairpin
inhibitor (or a control hairpin) followed by media condi-
tioning and exosome isolation. Successful knockdown of(B–E) Structural benefits of CDC exosomes. Representative Masson’s tri
and pooled morphometric analysis (C–E; n = 3 hearts per group) reveal
exosomes.
(F) In the chronic model, 3-month-old SCID Beige mice (n = 6 animals
intramyocardially with CDC exosomes or control. Functional measurem
(day 42), after which animals were sacrificed for histological analysis
(G–J) As in the acute MI model, CDC exosomes produce functional an
model of chronic MI.
*p < 0.05, **p < 0.01, and ***p < 0.001 using one-way ANOVA wi
represented as mean and SEM. See also Figures S2 and S3.
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and on NRVMs exposed to either control or miR-146a-
depleted exosomes (Figures S6B and S6C). The antiapop-
totic effect of CDC exosomes was evident by comparing
TUNEL positivity in untreated NRVMs (left column, Fig-
ure 5A) to that in NRVMs treated with control CDC
exosomes (right column, Figure 5A). Exosomes deficient
in miR-146a conferred less protection from oxidant stress
(middle column, Figure 5A) than did control CDC exo-
somes, but still significantly suppressed apoptosis. These
data hint that miR-146a underlies some, but not all, of
the beneficial effect of CDC exosomes. To further probe
this question in vivo, we implemented the sameMImodels
as in Figure 2 but injecting either a miR-146a mimic or a
miRNAmimic control. Mice injected withmiR-146amimic
during acute MI exhibited improved pump function (Fig-
ure 5B), decreased scar mass, and increased viable heart
tissue (Figures 5C–5F). In the chronic MI model, where
regeneration can be studied more rigorously, animals
treated with miR-146a showed only minor, statistically
insignificant functional improvement (Figures 5G and
S7A). Furthermore, histological analysis showed no differ-
ence in scar mass (Figures 5H and 5I). However, hearts
treated with miR-146a mimic did show increased viable
tissue, thicker infarcted walls (Figures 5J and 5K), and less
adverse remodeling than controls (Figures S7B–S7D). Eval-
uation of angiogenesis showed no significant differences
between the two groups (Figures 5L and S7G). However,
lower frequencies of cardiomyocyte apoptosis were
observed in the miR-146a-injected hearts (Figures S7H
and S7I), consistent with the in vitro data (Figure 5A).
Thus, in the chronic MI model, miR-146a reproduces
the cardiomyogenic and antiapoptotic effects, but not
the remaining functional and structural benefits, of CDC
exosomes (cf. Figures 2F–2J and S3A–S3C).
Exogenous miR-146a is known to suppress ischemia/re-
perfusion injury via targeting of Irak-1 and Traf6 (Cheng
et al., 2013), both involved in the toll-like receptor (TLR)
signaling pathway (Wang et al., 2013). TLR signaling un-
derlying innate immunity plays a major role in the pathol-
ogy of sterile inflammation, including MI (Arslan et al.,
2010; Feng et al., 2008; Oyama et al., 2004; Singh et al.,chrome-stained sections of hearts from each of the three groups (B)
decreased scar and increased viable mass in hearts injected with CDC
per group) underwent MI. Three weeks later, animals were injected
ents were taken 24 hr before injection (day 21) and 3 weeks later
.
d structural benefits in mouse hearts (n = 4 hearts per group) in a
th Tukey’s post hoc test and two-tailed Student’s t test. Data are
Figure 3. Exosome Inhibition Attenuates CDC-Mediated Benefits
(A) GW4869 inhibited exosome production in CDCs in a dose-dependent manner (n = 3 technical replicates).
(B) GW4869 does not affect CDC viability as shown by calcein assay of CDCs treated with GW4869 or its solvent DMSO (n = 4 technical
replicates).
(C and D) Neonatal rat cardiomyocytes (NRCMs) were cultured on chamber slides and treated with media conditioned by CDCs exposed to
either GW4869 or DMSO. NRCMs were then treated with culture media and after 5 days, slides were stained for Ki67 and TUNEL to assess
proliferation and apoptosis (n = 4 technical replicates per group).
(E) Pooled data for left ventricular ejection fraction (n = 8 animals per group).
(F–I) Representative Masson’s trichrome-stained heart sections from two groups (F) and pooled morphometric analysis (G–I; n = 4 hearts
per group) reveal impairment of CDC-mediated benefit as evident in pooled data for scar mass, viable mass, and infarct wall thickness (IWT)
in hearts injected with GW869-treated CDCs.
*p < 0.05 and **p < 0.01 using Student’s t test. Data are represented as mean and SEM. See also Figure S4.
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flammatory cytokines (Figure S2) and suppression of Irak1
and Traf6 by miR-146a (which is augmented in hearts
injected with CDC exosomes; Figure 4C) are consistent
with blunted TLR signaling. In addition, miR-146a sup-
presses NOX-4 (Vasa-Nicotera et al., 2011), which hasStebeen shown to impart oxidative stress and to potentiate
cardiac injury (Infanger et al., 2010), and SMAD4, a mem-
ber of the transforming growth factor b (TGF-b) profibrotic
pathway (Liu et al., 2012). To confirm that these targets are
indeed downregulated, we performed western blots on
chronic MI hearts 7 days after treatment with miR-146a.m Cell Reports j Vol. 2 j 606–619 j May 6, 2014 j ª2014 The Authors 611
Figure 4. miR-146a Is Highly Enriched in CDC Exosomes and Confers Therapeutic Benefit In Vitro and In Vivo
(A) Fold changes of miRNA abundance in CDC exosomes compared to NHDF exosomes (n = 4 independent experiments). Total RNA
(including miRNAs) was isolated from CDC exosomes and NHDF exosomes. qRT-PCR was performed on an miRNA array.
(B) Venn diagram showing the variable miRNA profile between CDC and NHDF exosomes. Font size reflects the magnitude of differential
expression of each miRNA.
(C) Infarcted mouse hearts treated with CDC-derived exosomes have elevated levels of miR-146a compared to NHDF exosome-treated hearts
(n = 2 animals per group, three technical replicates per group).
(legend continued on next page)
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miR-146a-treated hearts compared to mimic control (Fig-
ures 6A and 6B).We also found lower levels of myeloperox-
idase, a surrogate of neutrophil infiltration.DISCUSSION
Cardiosphere-derived cells have been shown to induce
therapeutic regeneration of the infarcted human heart. In
a form of injury traditionally thought to be irreversible,
CDCs led to shrinkage of scar and growth of new, func-
tional myocardium (Makkar et al., 2012). Similar effects
have been corroborated in animal models (Kreke et al.,
2012; Makkar et al., 2012). Here, we show that exosomes
reproduce CDC-induced therapeutic regeneration, and
that inhibition of exosome production undermines
the benefits of CDCs. Exosomes contain miRNAs, which
have the ability to alter cell behavior through paracrine
mechanisms (Figure 6B). Among these, we have identified
miR-146a as being particularly enriched in CDC exosomes.
When administered alone, miR-146a reproduces some, but
not all, of the salient benefits of CDCs and of CDC exo-
somes (Figure 3). Likewise, miR-146a-depleted exosomes
were still able to suppress cardiomyocyte apoptosis (Fig-
ure 5A), albeit more weakly than when miR-146a is pre-
sent. Treating hearts with miR-146a in a chronic model
of MI (after the scar is permanent) does reproduce the in-
crease in viable mass that is the signature of therapeutic
regeneration, but fails to mimic two key beneficial effects
of CDC exosomes: decreased scar mass and improved
global function. The increase in viable myocardium does
not suffice to increase function, possibly because of inade-
quate angiogenesis elicited by miR-146a (Halkein et al.,
2013). We conclude that miR-146a plays an important
part in mediating the effects of CDC exosomes, but alone
does not suffice to confer comprehensive therapeutic
benefit. Other miRNAs in the repertoire may exert synony-
mous or perhaps synergistic effects with miR-146a. For
instance, miR-22 (another miRNA highly enriched in(D) miR-146a protects stressed neonatal rat cardiomyocytes. Cardio
control then exposed to 100 mM hydrogen peroxide for 2.5 hr in serum
under study were derived from 20 to 30 rat pups from three different
(E) Microarray data showing fold differences in mRNA abundance betw
suppresses Irak1 and Traf6 in stressed neonatal rat cardiomyocytes.
(F) miR-146a-deficient animals have severely impaired cardiac functio
ejection fraction (n = 8 animals per group).
(G–J) Representative Masson’s trichrome-stained sections of hearts fr
hearts per group) reveal impairment of CDC-mediated benefit as ev
thickness (IWT) in hearts injected with GW869-treated CDCs.
*p < 0.05, {p < 0.05; **p < 0.01, and {{ p < 0.01 using Student’s t te
and SEM. See also Figures S5 and S6 and Table S1.
SteCDC exosomes) has been shown to be critical for adaptive
responses to cardiac stress (Gurha et al., 2012). Likewise,
miR-24 (also identified in CDC exosomes) modulates car-
diac fibrosis by targeting furin, a member of the profibrotic
TGF-b signaling pathway; overexpression of miR-24 in a
model of MI decreased myocardial scar formation (Wang
et al., 2012). The possible roles of these miRNAs as media-
tors of CDC exosome benefits, alone or in combination
with miR-146a, remain to be studied. Whereas dissection
of the active principles within CDC exosomes is worth-
while, deconstruction of the nanovesicles may be counter-
productive from a therapeutic perspective. CDC exosomes
are naturally cell permeant, and their lipid bilayer coat pro-
tects their payloads from degradation as particles shuttle
from cell to cell, so that the intact particles themselves
may be well suited for disease applications.
Our work implicates exosomes, and the miRNAs
they contain, as crucial mediators of CDC-induced cardiac
regeneration. CDCs exert diverse but coordinated effects:
they recruit endogenous progenitor cells and coax surviv-
ing heart cells to proliferate (Chimenti et al., 2010; Li
et al., 2010; Malliaras et al., 2013; Stastna et al., 2010);
on the other hand, injected CDCs suppress maladaptive
LV remodeling (Lee et al., 2011), apoptosis (Cheng et al.,
2012; Li et al., 2010), inflammation (Tseliou et al., 2014),
and tissue fibrosis (Tseliou et al., 2014) after MI. While it
is possible that CDCs secrete amedley of individual growth
factors and cytokines that collectively produce diverse
benefits, the involvement of master-regulator miRNAs
within exosomes would help tie together the various ef-
fects without postulating complex mixtures of numerous
secreted protein factors. Moreover, miRNAs are known to
confer long-lasting benefits and fundamental alterations
of the injured microenvironment (Osman, 2012), helping
to rationalize the sustained benefits of CDCs despite their
evanescent survival in the tissue (Malliaras et al., 2012).
CDC exosomes contain rich signaling information
conferred by a cell type that is the first shown to be capable
of producing regeneration in a setting of ‘‘permanent’’
injury, and confer the same benefits as CDCs withoutmyocytes were pretreated with 80 nM miR-146a mimic or mimic-
-free media (n = 4 technical replicates; neonatal rat cardiomyocytes
mothers).
een miR-146a and mimic-control treated cardiomyocytes. miR-146a
n and structure following acute MI. Pooled data for left ventricular
om three groups (G) and pooled morphometric analysis (H–J; n = 4
ident in pooled data for scar mass, viable mass, and infarct wall
st (*KO versus WT; {KO versus KO-R). Data are represented as mean
m Cell Reports j Vol. 2 j 606–619 j May 6, 2014 j ª2014 The Authors 613
Figure 5. miR-146a Improves Systolic Function in Acute and Chronic Mouse Models of MI
(A) miR-146a knockdown in CDC exosomes diminishes their capacity to protect stressed NRVMs in vitro (n = three technical replicates;
neonatal rat cardiomyocytes were derived from 20 to 30 rat pups from three different mothers). CDCs were transfected with either a
miR-146a inhibitor or a hairpin control with a sequence based on Caenorhabditis elegans microRNAs (HP-CTRL).
(B–F) Acute MI protocol data. Time course of left ventricular ejection fraction (n = 6 animals per group; B). Representative Masson’s
trichrome-stained sections of hearts from each of the two groups (C) and pooled morphometric analysis (n = 4 hearts per group) reveal
decreased scar mass, increased viable mass, and increased infarct wall thickness in animals treated with miR-146a compared to miRNA
control (D–F).
(G–L) miR-146a reproduces some of the structural and functional benefits seen in CDC-exosome-treated hearts in a mouse model of chronic
MI (miR-146a mimic or mimic control injected on day 21 after MI; n = 6 animals per group). Three weeks later (day 42), animals treated
(legend continued on next page)
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exosomes merit further development as cell-free therapeu-
tic candidates.EXPERIMENTAL PROCEDURES
Animal Subjects
All procedures related to animals have been conducted under
approved Institutional Animal Care andUse Committee protocols.Human CDC Culture
Endomyocardial biopsies from the right ventricular aspect of the
interventricular septum were obtained from healthy hearts of
deceased tissue donors. Cardiosphere-derived cells were derived
as described previously (Makkar et al., 2012). In brief, heart
biopsies were minced into small fragments and briefly digested
with collagenase. Explants were then cultured on 20 mg/ml fibro-
nectin (BD biosciences)-coated dishes. Stromal-like flat cells and
phase-bright round cells grew out spontaneously from the tissue
fragments and reached confluence by 2–3 weeks. These cells were
then harvested using 0.25% trypsin (GIBCO) and cultured in
suspension on 20 mg/ml poly d-lysine (BD Biosciences) to form
self-aggregating cardiospheres. CDCs were obtained by seeding
cardiospheres onto fibronectin-coated dishes and passaged. All
cultures were maintained at 5% CO2 at 37
C, using IMDM basic
medium (GIBCO) supplemented with 20% FBS (Hyclone), 1%
penicillin/streptomycin, and 0.1 ml 2-mercaptoethanol. Human
heart biopsy specimens, from which CDCs were grown, were ob-
tained under a protocol approved by the institutional review board
for human-subject research.Media Conditioning and Exosome Purification
Exosomes were harvested fromCDCs at passage 4. As a control, we
also isolated exosomes from normal human dermal fibroblasts
(NHDF). CDCs and NHDFs were conditioned in serum-free media
for 15 days at 100% confluence. Media was then centrifuged at
3,000 3 g for 15 min to remove cellular debris. Exosomes were
then isolated using Exoquick ExosomePrecipitation Solution
(System Biosciences), which yields high quantities of purified exo-
somes (Taylor et al., 2011). Exosome pellets were then resuspended
in the appropriate media and used for assays. Expression of the
conserved exosomemarker CD63was verified using ELISA (System
Biosciences). RNA content of exosome pellets was also quantified
using a Nanodrop spectrophotometer. For generation of miR-
146a-deficient exosomes, CDC were transfected in suspension
withmiRIDIANmiR-146a hairpin inhibitor or amiRIDIANhairpin
control (Thermo Scientific) and seeded on to fibronectin-coated
flasks. Exosomes were isolated from serum-free conditioned media
(48 hr conditioning).with miR-146a showed comparable cardiac function to control (G) but
also similar (I). Viability and infarct wall thickness were significant s
Analysis was done using Student’s t test; *p < 0.05, **p < 0.01, and **
S6 and S7.
SteExosomal RNA Degradation
Exosomal RNA degradation was done by suspending exosome pel-
lets in 2 ml of PBS. To one sample, 100 ml of Triton X-100 (Sigma
Aldrich) was added to achieve 5% triton concentration. Exosomes
were treated with 0.4 mg/ml RNase A treatment for 10 min at 37C.
Samples were further treated with 0.1 mg/ml Proteinase K for
20 min at 37C. RNA was purified from samples using an miRNA
isolation kit (System Biosciences). RNA levels were measured using
Nanodrop.Mass Spectrometry Analysis on Exosome Pellets
Proteins were prepared for digestion using the filter-assisted sam-
ple preparation (FASP) method (Wisniewski et al., 2009). Concen-
trations were measured using a Qubitfluorometer (Invitrogen).
Trypsinwas added at a 1:40 enzyme-to-substrate ratio and the sam-
ple incubated overnight on a heat block at 37C. The device was
centrifuged and the filtrate collected. Digested peptides were de-
salted using C18 stop-and-go extraction (STAGE) tips (Rappsilber
et al., 2003). Peptides were fractionated by strong anion exchange
STAGE tip chromatography. Peptides were eluted from the C18
STAGE tip and dried. Each fraction was analyzed with liquid chro-
matography-tandem mass spectrometry. Samples were loaded
to a 2 cm 3 100 mm I.D. trap column. The analytical column was
13 cm 3 75 mm I.D. fused silica with a pulled tip emitter. The
mass spectrometer was programmed to acquire, by data-dependent
acquisition, tandem mass spectra from the top 15 ions in the full
scan from 400 to 1,400 m/z. Mass spectrometer RAW data files
were converted to MGF format using msconvert. MGF files were
searched using X!Hunter (Craig et al., 2006) against the latest
spectral library available on the GPM at the time. MGF files were
also searched using X!!Tandem using both the native and k-score
(MacLean et al., 2006) scoring algorithms and by OMSSA
(Geer et al., 2004). Proteins were required to have one or more
unique peptides with peptide E-value scores of 0.01 or less from
X!!Tandem, 0.01 or less fromOMSSA, 0.001 or less and theta values
of 0.5 or greater from X!Hunter searches, and protein E-value
scores of 0.0001 or less from X!!Tandem and X!Hunter.Myocyte Isolation
Neonatal rat cardiomyoctes (NRCMs) were isolated from 1- to
2-day-old Sprague Dawley rat pups and cultured in monolayers
as described (Sekar et al., 2009).Angiogenesis Assay
Human vein umbilical vein endothelial cells were plated
on growth factor-deprived Matrigel (BD Biosciences) to assay
angiogenesis (Manoussaki et al., 1996). Cells were then incubated
with 7 3 108 and 4.0 3 108 CDC exosomes or NHDF exosomes,
respectively. Difference in doses reflects the different exosome
output from cells during conditioning. Cells were allowed toadverse remodeling was significantly attenuated (H). Scar mass was
tructural benefits (J and K), but scar mass was not reduced (I).
*p < 0.001. Data are represented as mean and SEM. See also Figures
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Figure 6. miR-146a Targets Genes Involved in MI Pathology
(A and B) Downregulation of known miR-146a targets in chronic MI
mouse hearts 7 days after injection of miR-146a or mimic control.
(A) Western blot for IRAK, TRAF6, SMAD4, NOX4, and MPO (a marker
of neutrophil infiltration). Each well is loaded with protein lysate
pooled from two hearts per group, so that the blot represents
pooled samples of two animals each with n = 4 technical replicates.
(B) Densitometric analysis of blot in (A) normalized to glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH).
(C) Schematic of our working hypothesis. CDCs promote functional
and structural benefits in the injured myocardium in a primarily
paracrine manner. CDCs secrete exosomes that contain miRNAs that
mediate benefits in the injured myocardium. These miRNAs target
transcripts in the various compartments of the myocardium, which
ultimately leads to increased cardiac function, increases in viable
tissue, and decrease of scar after MI.
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doses might be representative of the relative exosome production
in vivo. Four hours later, tube formation was measured.
In Vitro Cardiomyocyte Assay
Exosome Treatment
We plated 1.5 3 104 NRCMs in fibronectin-coated eight-chamber
slides. After 5 days, media was replaced with new fresh media con-
taining 3.53 108 or 23 108 CDC or NHDF exosomes, respectively.
Cells were then fixedwith 4%paraformaldehyde for 30min at 4C.
Chambers were washed three times with cold PBS then blocked
and permeabilized with Dako/0.1% Saponin (Invitrogen) for
1 hr at 37C. Cells were incubated (overnight, 4C) with rabbit
anti-Ki-67 (1:100) primary antibody and mouse anti-a-sarcomeri-
cactinin (Abcam). Cells were then washed three times with PBS
and incubated with goat antimouse (Cy5) and goat antirabbit
(FITC) in TUNEL stain solution for 1 hr at 37C. Slides were then
washed three times in PBS, stained with 1:8,000 40,6-diamidino-
2-phenylindole stain solution, and mounted using Prolong
antifade solution(Invitrogen). Slides were imaged using confocal
microscopy.
Cardiomyocyte Stress Assay
NRCMs were plated in a monolayer on fibronectin-coated 12-well
plates and treated with either 40 nM of miR-146a or mimic for
24 hr. Media was then changed and cells were washed three times
with PBS. Cells were then stressed using of hydrogen peroxide
(100 mM H2O2 in serum free media for 2 hr) or cobalt chloride
(5 mMCoCl2 in serum-free media for 2 hr). Viability was measured
by washing cells with PBS and treating with 20 mM Calcein PBS
solution for 20 min at 37C in dark conditions. Fluorescence was
read using a Soft Max Pro 5 Plate Reader (Molecular Devices). Data
per well is the average of nine consecutivemeasurements. A second
model used in this study involved plating cardiomyocytes on
25 mm precoated glass coverslips (Fischer Scientific) in six-well
plates. Cells were stressed using 50 mMH2O2 for 15min followed in-
cubation with transwell membrane inserts containing CDCs or in-
cubationwithCDCexosomes for 4hr.Cellswere thenwashed,fixed
withparaformaldehyde, andstained foranalysis as explainedabove.
Exosome Inhibition in CDCs
CDCswere grown to confluence in T175 flasks. For in vitro studies,
CDCs were conditioned for 15 days in 20 mM GW4869 (Sigma
Aldrich), serum-free media, or serum-free media containing an
equivalent volume of DMSO. For in vitro transwell insert assays
of cardiomyocyte stress, we treated CDCs with 20 mM GW4869
(Sigma Aldrich), or 5 mM Spiroepoxide (Santa Cruz Biotechnology)
for 12 hr. CDCs were then washed three times in PBS and sup-
planted with serum-free media. Inserts containing treated CDCs
were then added into six-well plates containing cardiomyocytes.
For in vivo studies, CDCs were treated with 20 mM GW4869 or
an equivalent volume of DMSO for 12 hr. Prior to injection,
CDC flasks were washed twice with PBS, trypsinized, and counted;
105 CDCs were injected per animal.
Acute and Chronic Myocardial Infarction Model
Three-month-oldmale severe combined immunodeficient (SCID)-
beige mice were anesthetized with isoflurane. Following surgical
Stem Cell Reports
Exosomes as Mediators of Cardiac Regenerationpreparation, a 2 cm vertical incision was performed in the midcla-
vicular line for a lateral thoracotomy. The left anterior descending
was ligated using 7-0 silk. Animals were injected with exosomes,
miRNAs, CDCs, or media control at two peri-infarct sites with a
volume of 40 ml per injection (Smith et al., 2007). For the chronic
model of MI, animals were infarcted as described above without
any treatment administration. Three weeks later, the animals
were given the treatment in the same manner as above. For
exosome treatments, pellets were resuspended in Iscove’sModified
Dulbecco’s (IMDM) basal media. Animals were injected with 2.83
109 and 1.56 3 109 of CDC and NHDF exosomes, respectively.
miRNA-treated animals were injected with 80 ng of miR-146a or
miRNAmimic control. In brief, miRIDIANmiR-146a or miRIDIAN
negative control (Thermo Scientific) was vortexed in Dharmafect
(Thermo Scientific) transfection reagent and IMDM basal media
and incubated for 10min at room temperature to allow complexes
to form. miRNA complexes were then resuspended in IMDM for
injection. For CDC treatments, animals were injected with 105
CDCs as described (Li et al., 2012).
Echocardiography
SCID beige mice underwent echocardiography 24 hr (baseline),
14 days, and 4 weeks after surgery using Vevo 770 Imaging System
(Visual Sonics) (Smith et al., 2007). After induction of light general
anesthesia, hearts were 3D imaged in the long axis view at the level
of maximum left ventricular diameter. Left ventricular ejection
fraction was measured with Visual Sonics version 1.3.8 software
from 2D views of LV end-diastolic and LV end-systolic area. Each
animal/time point was measured multiple times and the average
was used for statistical analysis.
Histology
Animals were sacrificed 4 weeks after MI. Hearts were harvested
and a transverse cut was made slightly above the MI suture. The
apical portion was then imbedded in optimum cutting tempera-
ture solution in a base mold/embedding ring block (Tissue Tek).
Blocks were immediately frozen by submersion in cold 2-methyl-
butane. Hearts were sectioned at a thickness of 5 mM.
Masson’s Trichrome Staining
Two slides containing a total of four sections per heart were stained
usingMasson’s trichrome stain. In brief, sectionswere treated over-
night in Bouin’s solution. Slides were then rinsed for 10min under
running water and stained with Weigert’s hematoxylin for 5 min.
Slides were then rinsed and stained with scarlet-acid fuchsin for
5 min and rinsed again. Slides were then stained with phospho-
tungstic/phosphomolybdic, aniline blue, and 2% acetic acid for
5 min each. Slides were then rinsed, dried, and mounted using
DPX mounting media.
Morphometry
Morphometric analysis of heart sections was performed using
Image J software (Makkar et al., 2012). In brief, 2D images of
stained sections were split into blue, red, and green channels
(only the blue was used). Infarct size was made by measuring
area and intensity of blue in each section to calculate infarct size.
Percent viable and infarct mass were calculated by averagingStepercent infarct across four sections analyzed per heart. Infarct
and viable masses were calculated as the product of the infarct or
viable tissue, the height of the average mouse heart (3 mm) and
the specific gravity of heart tissue (1.05 g/ml). Infarct wall thick-
ness was calculated by measuring the thinnest area of the infarct.
In the chronic model of MI where significant hypertrophy and
adverse remodeling took place, we adjusted the viable mass of
each heart based on the derived mass of cardiomyocytes in the tis-
sue. Myocyte mass was obtained by measuring the cross-sectional
area of perpendicularly sectioned cardiomyocytes (defined as
round cells with red cytoplasm and a visible nucleus in the center).
We measured at least 25 myocytes per heart. Myocyte volume was
quantified using the simplifying assumption of a cylindrical shape;
mass was derived bymultiplying volumes by the specific gravity of
a cardiomyocyte (1.15mg/ml). The viablemass of eachmouse heart
was divided by the mass of the cardiomyocytes in that heart.
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